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The presenter has no potential or 
actual conflicts of interest to disclose 
in association with this presentation. 
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Objectives
 Examine the legal status and use of marijuana and its 
derivatives in the United States.
 Describe e-cigarettes & compare/contrast vaping and juuling 
and FDA stand on these products.
 Describe the impact that vaping and other pharmacological 
therapies for tobacco smoking cessation.
 Examine the adverse effects of using recreational e-
cigarettes, marijuana, vaping, and juuling.
 Raise public awareness to prevent adolescents, teens, and 
adults from smoking e-cigarettes and tobacco products.
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Background on Marijuana  
 Comes from the plant Cannabis Sativa and 
Cannabis Indica 
Has been used for more than 4,000 years  
 Earliest documentation of therapeutic use of 
marijuana dates back to the fourth century BC in 
China4
(2018). Plants Profile for Cannabis sativa (marijuana). [online] Available at: https://plants.usda.gov/core/profile?symbol=casa3 [Accessed 13 Dec. 2018] 
Plants.usda.gov.
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Background on Marijuana 
Marijuana was listed in the US Pharmacopoeia 
from 1850- 1942
 In 1970, FDA listed marijuana as a scheduled I 
controlled substance7
 The Cannabis plant contains over 400 different 
chemical compounds 
 The two most common are:
• Tetrahydrocannabinol (THC) 
• Cannabidiol (CBD) 
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Background on Marijuana 
Cannabis Sativa
Tall thin stemmed with 
narrow leaves
Longer time to mature 
Medicinal derivate with  
lower CBD levels 
Medicinal derivate have 
higher THC levels 
Cannabis Indica 
Short stemmed with 
wide leaves  
Faster growing and 
higher yields
Medicinal derivate have 
higher CBD levels  
Medicinal derivate have 
lower THC levels
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Background on Marijuana 
Cannabinoids is a term used to describe a 
compound that agonizes the cannabinoid 
receptors (CB)7
 CB1
• Found in nervous system 
 CB2
• Located primarily in the peripheral system and recent data 
supports in the nervous system 
 Both receptors have also been identified in the T and B 
lymphocyte9
The receptors are G protein linked 
neuromodulators that inhibits adenylate 
cyclase in a dose dependent manner7
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Background on Marijuana 
 THC 




• Changes mood 
• Impairs cognitive functions
 Higher doses
 Hallucinations, delusion, 
and psychosis 
 Long-term effects
• Impairment in cognitive 
function
 CBD
 Not a psychoactive but 




• Change in appetite 
• Weight gain or loss
• Decrease inflammation 
• Reduce pain 
• Reduce insomnia 
 Long-term effects
• Not well studied 
8
Recreational Use 
Smoking is the most common use of 
marijuana 
 Joint/blunt, pipe, or a bong
Assorted with food 
Mixed with a beverage as a tea
Dabbing 
9
Place in Medicine 
FDA has not approved marijuana safe and 
effective and remains a schedule I controlled 
substance 
FDA approved derivatives of marijuana: 
 Epidiolex® (Cannabidiol) 





The Daily Marijuana Observer. (2018). EPIDIOLEX (cannabidiol) Oral Solution – the First FDA-approved Plant-
derived Cannabinoid Medicine – Now Available by Prescri. [online] Available at: https://mjobserver.com/united-
states/epidiolex-cannabidiol-oral-solution-the-first-fda-approved-plant-derived-cannabinoid-medicine-now-available-
by-prescription-in-the-u-s/ [Accessed 14 Dec. 2018].
Epidiolex® (Cannabidiol) 
 Approved for 
 Treatment of seizures associated with Lennox-Gastaut 
syndrome or Dravet syndrome3
 Lennox-Gastaut Syndrome 
 Onset between the age of 2 years to 18 years of age
Dravet Syndrome 




 Initial: 2.5 mg/kg twice daily 
•Maintenance dose of 5 mg/kg may be increased after 
tolerating for 1 week 
 Max dose: 10 mg/kg twice daily 
 Adjustment3
 Moderate hepatic impairment (Child-Pugh class B) 
•Initial: 1.25 mg/kg twice daily, may increase after 
tolerating for 1 week to a dose of 2.5 mg/kg twice a day 
 Maintenance dose of 2.5 mg/kg
 Max dose: 5 mg/kg twice daily
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Epidiolex® (Cannabidiol) 
 Severe hepatic impairment (Child-Pugh class C)3
 Initial: 0.5 mg/kg twice daily, may increase after tolerating 
for 1 week to a dose of 1 mg/kg twice daily 
• Maintenance dose of 1 mg/kg
 Max: 2 mg/kg twice daily
 Monitor
 ALT, AST, and total bilirubin
 Adverse effects 









Akorn.com. (2018). [online] Available at: 
http://www.akorn.com/documents/catalog/sell_sheets/17478-762-06.pdf 
[Accessed 14 Dec. 2019].
Marinol® (Dronabinol) 
FDA approval to treat:6
 Anorexia in patients with AIDS





 Initial: 2.5 mg twice daily 1 hour prior to meals 
•May increase dose gradually based on 
response to medication 




 Initial: 5 mg/m2 1 to 3 hours prior to 
chemotherapy, then 5 mg/m2 per dose every 2 
to 4 hours after therapy. Total of 4 to 6 doses 
per day5
•May increase dose gradually based on 
response, increments of 2.5 mg/m2




Syndros.com. (2018). SYNDROS | The First & Only FDA-Approved Liquid Dronabinol. 
[online] Available at: https://www.syndros.com/ [Accessed 14 Dec. 2018].
Syndros™ (Dronabinol) 
FDA approval to treat:10
 Anorexia in AIDS patients





 Initial: 2.1 mg twice daily 1 hour prior to 
meals 
•May increase dose gradually based on 
response to the medication
•Increments of 2.1 mg for the latest 
meal first, then may increase to 2.1 mg 
for both doses




 Initial: 2.1 mg/m2 1 to 3 hours prior to chemotherapy, 
then 2.1 mg/m2 per dose every 2 to 4 hours after 
therapy. Total of 4 to 6 doses per day 9
•Dose rounded to nearest 0.1 mg 
•May increase dose gradually based on response to the  
medication
•Increments of 2.1 mg/m2 for the latest meal first, then 
may increase to 2.1 mg/m2 for both doses
 Max dose: 12.6 mg/m2 per dose9
22











Cesamet.com. (2018). Cesamet (nabilone): Dosing & Administration. [online] 




 Refractory nausea and vomiting associated with 





 Initial: 1 to 2 mg twice daily 
• May be used 2 to 3 times a day throughout chemotherapy  
regimen 
• Continue up to 48 hours after last chemotherapy dose
 Max dose: 6 mg per day divided into 3 doses
Monitor
 Heart rate, blood pressure, and worsening of symptoms  
 Adverse effects 
 Central nervous system 
 Xerostomia
 Visual disturbances  
26





 Cancer and chemotherapy-induced nausea
Non-FDA approval 
 Neuropathic pain
 Treatment of spasticity associated with multiple 
sclerosis
27
Status of Marijuana in United 
States 
 The use of marijuana federally remains prohibited8
 Recreational approval:
 Alaska, California, Colorado, District of Columbia, Maine, 
Massachusetts, Michigan, Nevada, Oregon, Vermont, and 
Washington 
 Approved for Medical use:
 Arizona, Arkansas, Connecticut, Delaware, Florida, 
Hawaii, Illinois, Louisiana (can not be smoked), Maryland, 
Minnesota, Missouri, Montana, New Mexico, New 
Hampshire, New Jersey, New York, North Dakota, Ohio, 
Oklahoma, Pennsylvania, Rhode island, Utah, West-




Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. [online] Centeronaddiction.org. Available at: 
https://www.centeronaddiction.org/e-cigarettes/recreational-vaping/what-parents-should-know-about-different-vaping-devices [Accessed 15 Dec. 2018].
Vaping 
The act of using an electronic device to 
inhale or exhale an aerosol containing 
multiple chemicals
 Nicotine 
 Propylene glycol (PG) and/or vegetable glycerin 
(VG) base 
 Flavoring agents 
 Water 
Think of vaping as an umbrella term for 








•Mechanical modified nicotine deliver system (MODs) 
kits
•Juul




 Throat hit 
•Soft, medium, and hard 
31
Electronic Cigarettes/Cig-likes 
 First generation of vaping devices 
32
Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. [online] 
Centeronaddiction.org. Available at: https://www.centeronaddiction.org/e-cigarettes/recreational-vaping/what-
parents-should-know-about-different-vaping-devices [Accessed 15 Dec. 2018].
Pen Kits
 Second generation of vaping devices 
33
Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. 
[online] Centeronaddiction.org. Available at: https://www.centeronaddiction.org/e-
cigarettes/recreational-vaping/what-parents-should-know-about-different-vaping-devices [Accessed 15 
Dec. 2018].
Mechanical Modified Nicotine 
Deliver System (MODs) Kits
Third generation 
Longer battery life than previous devices 
Delivers higher amounts of nicotine as 
compared to previous devices 
34
Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. [online] Centeronaddiction.org. 
Available at: https://www.centeronaddiction.org/e-cigarettes/recreational-vaping/what-parents-should-know-about-different-vaping-devices 
[Accessed 15 Dec. 2018].
Electronic Hookah 
 Third generation 
35
Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. 
[online] Centeronaddiction.org. Available at: https://www.centeronaddiction.org/e-cigarettes/recreational-
vaping/what-parents-should-know-about-different-vaping-devices [Accessed 15 Dec. 2018].
Juul
 The term Juuling has resulted from its growing 
popularity among users
 Similar to a USB
Marketed in various flavors 
 Easy to carry and recharged 
36Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. [online] Centeronaddiction.org. Available at: 
https://www.centeronaddiction.org/e-cigarettes/recreational-vaping/what-parents-should-know-about-different-vaping-devices [Accessed 15 Dec. 2018].
Smoking Cessation 
 Vaping may be safer compared to smoking 
cigarettes and other combustible tobacco products
 Evidence from studies supports that vaping has 
less toxic elements than combustible products
 Long term effects are not known yet as this is a 
new trend 
 For the youth this is a problem because we are 
introducing nicotine at an early age and their 
brains are still developing  
 Creating an addiction to these devices 
Heavy smokers may need to consider bigger 
device and larger PG percentage 
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Smoking Cessation 
 Vaping is not approved among the guidelines as 
an aid for quitting 
Methods to stop smoking 
 Counseling 
 Pharmacological 
•Nicotine replacement products 
OTC
 Prescription 








Cigarette use Week 1-6 Week 7-8 Week 9-10
≤ 10 per day 14 mg 7 mg None 
> 10 per day 21 mg 14 mg 7 mg 
Week 1-6 Week 7-9 Week 10-12 
1 gum every 1 to 2 
hours 
1 gum every 2 to 4 
hours 
1 gum every 4 to 8
hours 
2 mg gum 4 mg gum 
If 1st cigarette smoked 30 minutes or 
later after waking up 
If 1st cigarette smoked within 30 
minutes after waking up 
Smoke < 25 cigarettes a day Smoke > 25 cigarettes a day 
Smoking Cessation 
•Non-nicotine replacement medications 
 These agents serve as an aid to alleviate 
nicotine withdrawal symptoms and 
decreases the surges of dopamine, that is 
responsible for the reward associated with 
smoking
40
Drug Day 1-3 After day 3
Zyban® 150 mg every morning 150 mg twice daily 







 Black boxed warning:
 Risk of suicidal thinking
 Contraindication12
 Patients with seizure disorder
 History of anorexia
 Using within 14 days of discontinuing MAO inhibitors 








 CrCl<30 mL/minute initial: 0.5 mg once 
daily by mouth 
 Max dose: 0.5 mg twice daily
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Smoking Cessation 
 Smoking is the leading cause of preventable death 
 480,000 deaths per year in the US associated with 
smoking10
 6 million death per year world wide associated with 
smoking10
 Smoking of tobacco is linked to many health problems 




 Lung disease 
 Infertility in women 
43
Quit Smoking 
Limited evidence that ENDS may be 
effective as an aid to promote 
smoking cessation 
No data to recommend vapes over 
approved products 
44
Potential Harm of Vaping
Bronchiolitis obliterans “Popcorn 
lung”
Nicotine addiction 
 Not considered a carcinogen, but may 





Judith Marcin, M. (2019). Popcorn lung: Causes, symptoms, and treatment. [online] Medical News 
Today. Available at: https://www.medicalnewstoday.com/articles/318260.php [Accessed 8 Jan. 
2019].
Side Effects/Risks of Vaping
Irritation to the eyes and throat 
Elevation of heart rate and blood 
pressure
E-liquid poisoning if ingested
Device battery explosions 
47
Under 18 years of Age 
Evidence from the 2018 National 
Academies of Sciences, Engineering, and 
Medicine Report (NASEM) supported that 
the use of ENDS increases the risk of 
children and teenagers smoking tobacco
Moderate evidence that ENDS use 
increases frequency and intensity of 
subsequent tobacco products 
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2nd Hand Smoking 
Less compared to combustible 
tobacco 
Vaping indoors increases the 
concentrations of particulate matter 
and nicotine in indoor environment 
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Public Awareness 
From the data it is apparent that 
vapes may be less harmful for adults 
that smoke, but this does not apply  
for children and adolescent 
According to the FDA many of adult 
smokers started at an early age5
 90% started before the age of 18
 95% started before the age of 21
 1% started after the age of 26
50
Data from the 2018 National Youth 
Tobacco Survey (NYTS)
 Information provided by a collaboration of the 
FDA and CDC
 The population of the survey were middle and 
high school students, regarding their use of 
ENDS5
 78% increase among high school students from 
2017 to 2018
 48% increase among middle school students  
from 2017 to 2018
 Total number of students using ENDS increased 
from 1.5 million to 3.6 million
•67.8% of those students used flavored ENDS
51
FDA 
FDA is aware of this alarming data and has 
created tools to address this problem 
 Launched a Youth Tobacco Prevention Plan 
 Launched the  “The Real Cost”  prevention 
campaign 
 Task force to crack down on retailers who are 
selling illegal ENDS to the youth 
 Partnered with Federal Trade Commission 
 Stricter flavoring policies for all flavored ENDS 
except for  
•Tobacco, mint, and menthol flavor 
52
Take Home Points
Use approved FDA methods for smoking cessation 
 Long term effects of vaping is unknown
 Adolescents should avoid all tobacco and ENDS, 




True False OR 
54
True or False  
The same therapeutic effects can be 






True or False 
CBD oil has FDA approved indication 






True or False 
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